Compare Aurora Cannabis Inc (ACB) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aurora Cannabis Inc vs Biogen Inc — how do they compare? Aurora Cannabis Inc trades at $3.54 (market cap $223.59M), while Biogen Inc trades at $204 (market cap $30.13B). The key difference: Biogen Inc is far larger — about 134.8× Aurora Cannabis Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Aurora Cannabis Inc nearer its low. Which is the better fit depends on your goals.
| ACB | BIIB | |
|---|---|---|
Market Cap | $223.59M | $30.13B |
Sector | Health | Health |
52-Week High | $6.23 | $216.63 |
52-Week Low | $2.58 | $128.93 |
Enterprise Value | $168.09M | $37.20B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aurora Cannabis Inc
Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.
Read more on ACB →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
